General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis (PFIC).
Last updated August 6, 2025
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive
Last updated July 31, 2025
Casgevy (exagamglogene autotemcel)
Status:
Active negotiation
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Sickle cell disease
Last updated July 29, 2025
Casgevy (exagamglogene autotemcel)
Status:
Active negotiation
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Transfusion-dependent ?-thalassemia
Last updated July 29, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Last updated July 24, 2025
Status:
Concluded with an LOI
Manufacturer:
Kyowa Kirin Canada, Inc.
Indication:
X-Linked Hypophosphatemia
Last updated July 21, 2025
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated July 14, 2025
Status:
Concluded with an LOI
Manufacturer:
Ultragenyx Pharmaceutical Inc.
Indication:
Homozygous Familial Hypercholesterolemia
Last updated July 8, 2025
Status:
Negotiations were not pursued
Manufacturer:
Sun Pharma Canada Inc.
Indication:
Acne Vulgaris
Last updated July 4, 2025
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Generalized myasthenia gravis (gMG)
Last updated July 3, 2025